Kornimate/medical-research-clean huggingface dataset:
a study for pd-1 antibody js001 in msi-h advanced or recurrent colorectal cancer

Conditions: Colorectal Cancer

Summary: to observe the efficacy of pd-1 antibody js001 in the treatment of participants with microsatellite instability-high (msi-h) advanced or recurrent colorectal cancer, so as to provide sufficient evidence for msi-h as a biomarker of pd-1/pd-l1 inhibitor.


Eligibility criteria:
inclusion criteria: * fully understand the study and sign informed consent voluntarily; * histologically confirmed advanced or recurrent colorectal cancer, and msi detection identified msi-h; * patients who have previously received first-line or above chemotherapy or targeted therapy and failed to the treatment or experienced recurrence; * at least one measurable lesion (recist 1.1); * agree to provide tumor tissue samples and pathology reports related to the specimens; * aged 18 to 75 years, gender not limited; * eastern cooperative oncology group(ecog) performance status(ps) 0-1; 8. expected survival ≥3 months; * laboratory test values must meet the following standards within 7 days before enrollment; * women of reproductive age must confirm that the serum pregnancy test is negative and agree to use effective contraceptive measures during the study drug use exclusion criteria: * uncontrolled or symptomatic hypercalcemia; * had major surgery or had not fully recovered from previous surgery within 4 weeks before enrollment; * central nervous system(cns) metastases; * bone metastases; * uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently) allow the patient to have a catheter indwelling; * having a history of idiopathic pulmonary fibrosis, organic pneumonia; * uncontrolled active infection, including but not limited to acute pneumonia; * have other malignant tumors at the same time; * the patient has any active autoimmune diseases or a history of autoimmune diseases; * liver diseases of known clinical significance, including active viral viral hepatitis, alcoholic hepatitis or other hepatitis, cirrhosis, fatty liver and hereditary liver diseases. * previous use of anti-pd-1 antibody, anti-pd-l1 antibody, anti-pd-l2 antibody or anti-ctla-4 antibody; * patients with active tuberculosis (tb); * received systemic immunosuppressive within 4 weeks prior to day 1 of the first cycle; * pregnancy test positive; * known human immunodeficiency virus (hiv) infection; * a history of severe allergy, anaphylaxis or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; * those who are known to be allergic to biological drugs produced by hamster ovary cells in china, or to citric acid monohydrate, sodium citrate dihydrate, mannitol and polysorbate (components of the experimental drugs); * patients who have previously received allogeneic stem cells or parenchymal organ transplantation.
study comparing desirudin with heparin to prevent vein clots after heart and lung surgery

Conditions: Deep Venous Thrombosis

Summary: a blood clot in the veins, also known as deep venous thrombosis (dvt), is one of the most common complications after surgery. this may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary embolism (pe). after heart surgery the incidence of dvt ranges from 20-48% and following lung surgery the incidence is 19-26%. in order to decrease the likelihood of this complication, patients receive by injection a blood thinning medicine. heparin is the usual medicine used for this purpose following heart and lung surgery. recently there have been reports that other medicines may be more effective than heparin for this purpose. also there have been reports that some patients develop antibodies to heparin. when this occurs, this may prevent the heparin from being effective and may even promote the formation of blood clots. antibodies to heparin may be present more often following heart and lung surgery than other types of surgery. there is a new medicine called desirudin (iprivask), which may be used instead of heparin to prevent blood clots following heart and lung surgery. desirudin is currently approved by the fda to prevent blood clots following hip surgery. the purpose of this study is to compare desirudin with heparin for the prevention of vein clots after heart and lung surgery.


Eligibility criteria:
inclusion criteria: * patients who are scheduled for elective cardiac or thoracic surgery. * age \> 18 years of age. exclusion criteria: * patients with a clinical suspicion or a documented history of dvt/pe * patients who may require anticoagulation during the post-op period. (i.e. patients with a history of a-fib, scheduled for a maze procedure or placement of a mechanical valve, or those on coumadin/iv heparin preoperatively) * patients who have a history of hit or if there is a suspicion of the patient having hit pre-operatively. * documented allergy to heparin, desirudin, or lepirudin * patients with a history of coagulation disorder * platelet count\< 100 x109 /dl * active bleeding * serum creatinine ≥ 1.5 mg/dl or crcl ≤ 30 ml/min * patients with a baseline coagulopathy (inr \> 1.5 or aptt \> 45 sec) * patients with liver disease * pregnancy * patients who require ventricular assist devices before or after surgery

Keywords: deep venous thrombosis dvt heparin induced thrombocytopenia hit direct thrombin inhibitor
integrated treatment to persons with mental disorders and co-occurring substance use disorders

Conditions: Anxiety Disorders; Mood Disorders; Substance Use Disorders

Summary: the purpose of this study is to determine whether integrated treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.

patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. this also calls for an integration of the services on an organizational level. this approach of integrating services and treatment approaches for both diseases in a comprehensive way is called integrated treatment. several studies have shown that integrated treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. the over-all aim of this study is to evaluate the effects of evidence-based integrated treatment in anxiety and/or depression with co-occurring substance use disorders. the effects of the treatment will be assesses on changes in substance use and psychopathology. comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of substance use disorder * clinical diagnosis of anxiety disorders * clinical diagnosis of nonpsychotic mood disorders * written consent * planning to live in the catchment area during the treatment exclusion criteria: * schizophrenia spectrum disorders * other psychotic disorders * mental retardation * nicotine abuse/dependency only * prescription drug abuse/dependency only * planning to move out of the catchment area during the study * not able to read or write norwegian

Keywords: mental health substance use treatment
interest of teg6s® in reducing transfusion needs during postpartum haemorrhage

Conditions: Postpartum Hemorrhage

Summary: the main objective of this study is to evaluate fibrinogen consumption, transfusion need, and other security outcomes in women with postpartum hemorrhage of 1000 ml or more, before and after the implementation of a teg6s® device at a level iii maternity unit (centre hospitalier sud francilien, corbeil-essonnes, france).

acquired obstetrical coagulopathy during massive postpartum hemorrhage (pph) is a serious and frequent complication of delivery. it has been shown that fibrinogen levels are the first to fall during pph, and that a level inferior to a threshold of 2g/l is strongly associated with progression to severe pph, hemostatic impairment, transfusion, and invasive hemostatic procedures. the clinical diagnosis of coagulopathy is difficult, and the biological diagnosis by usual laboratory tests is often delayed, leading to the empirical administration of fibrinogen and blood products, sometimes unnecessary. the teg6s® is a viscoelastic testing device performed on whole blood, which allows a reliable assessment of hemostasis and coagulation quality in about ten minutes. the anomalies detected by the teg6s® allow for the early diagnosis of acquired coagulopathy, especially hypofibrinogenemia. its use during the management of pph would therefore allow for transfusion savings and potential economic benefits, in addition to improving patient prognosis through early and appropriate treatment (including the absence of early "blind" treatment in the absence of coagulopathy).

Eligibility criteria:
inclusion criteria: * woman of 18 years old or more * delivery at the level iii maternity of centre hospitalier sud francilien (chsf) (corbeil-essonnes, france) between 2022 and 2024, except deliveries during cyber-attack period at chsf (from august 2022 to december 2022 included), due to uncertainty over the completeness of the data. * presenting postpartum hemorrhage with estimated blood loss of 1000ml or more * no constitutional hemostasis anomaly * no treatment interfering with hemostasis * no use of blood products and/or pro-coagulant products before delivery exclusion criteria: - patient informed of the research and refusing the use of the data
electronic kidclot interactive thrombosis/thrombophilia education; a quality assurance initiative

Conditions: Health Literacy; Anticoagulation

Summary: effective patient education improves health literacy and engagement thus improving long-term health outcomes. health literacy is imperative to make informed health decisions and relies on the ability to obtain, process and understand health information; and is the cornerstone of safe health management. it is necessary to evaluate educational initiatives to determine their effectiveness in knowledge translation. a more effective way to provide patient education is to utilize media technology. current education styles do not teach patients in the best way as they are not consistent with how people of all ages currently learn (through technology). in addition, patient teaching most commonly occurs during highly stressful times like hospital visits with new diagnoses. current patient educational methods are costly given the amount of health provider time required. electronic kite teaching modules are infographic visual representations that present information quickly and clearly, integrating words and graphics to tell a story to reveal information. infographic presentations are tools which facilitate self-directed learning with understandable, accessible information presented in an engaging way with an aim to enhance learning for children and their families. patients are able to learn at a pace consistent with their learning style to facilitate knowledge development and health literacy.

a more effective way to provide patient education is to utilize media technology. current education styles do not teach patients in the best way as they are not consistent with how people of all ages currently learn (through technology). in addition, patienteaching most commonly occurs during highly stressful times like hospital visits with new diagnoses. current patient educational methods are costly given the amount of health provider time required. electronic kite teaching modules are infographic visual representations that have been developed to provide patient teaching related to warfarin and its management. how much patients have learned will be assessed using the kidclot validated knowledge quizzes. children 8 years and older to have cognitive capacity will complete the quizzes if able. caregivers will complete all quizzes linked with the modules they have completed. patients may be enrolled into the appropriate cohort based on the health provider decision for management. 1. warfarin international normalized ratio (inr) testing 2. warfarin with home inr testing 3. warfarin transition from home inr testing to warfarin self management.

Eligibility criteria:
inclusion criteria: * pediatric patients and their caregivers who are receiving treatment with anticoagulant therapy. exclusion criteria: * non-english speaking patients.

Keywords: warfarin child
spanish study to analyze the histopathological, ultrastructural and microbiological findings obtained in autopsies of patients who died due to covid-19

Conditions: Covid19

Summary: the aim of this study is prospectively analyzing the histopathological, ultrastructural and microbiological findings from autopsies performed on patients with covid-19.

the aim of this study is to increase the knowledge of the pathogenic mechanisms of the covid-19 disease, that will allow us to improve the design of clinical and therapeutic strategies against the disease. this is the tool to improve the prognosis of patients with covid-19. the performance of systematic and regulated autopsies can help to manage it. however, despite the need to generate this knowledge and the strong impact on mortality caused by the covid-19 pandemic, the evidence from post-mortem studies is very limited.

Eligibility criteria:
inclusion criteria: * patients with covid-19 infection confirmed by pcr. * death related to active infection by covid-19 or its complications. * informed consent given by the subject's relatives to perform an autopsy according to the autonomous community requirements. * informed consent given by the subject's relatives for the inclusion of samples in the biobank. exclusion criteria: * covid-19 infection diagnosed exclusively by serological methods. * advanced or terminal chronic disease. * inadequate security level of the autopsy room.

Keywords: covid-19 autopsy histopathological findings ultrastructural findings microbiological findings
drug management of rheumatoid arthritis in covid-19 context : impact on therapeutic de-escalation

Conditions: Rheumatoid Arthritis; COVID

Summary: the current situation of sars-cov-2 pandemic generates fears in the general population. among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. most patients with juvenile rheumatoid arthritis benefit from long-term immunmodulatory therapy (dmard - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (nsaids) or corticosteroids.the present study will characterize this issue by defining the proportion of patients whose usual treatment of rheumatoid arthritis has been modified in relation to the actual sanitary crisis.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis satisfying acr/eular criteria * ongoing dmard therapy exclusion criteria: * inhability to consent
workplace-based hiv self-testing among men in uganda (wise-men)

Conditions: HIV Infections

Summary: this study seeks to determine whether workplace delivery of hiv self-testing will lead to an increase in uptake of hiv testing and subsequent linkage to care or prevention services among men in uganda.

the current coverage of hiv testing and counseling in uganda is 60% with only 34% of these being men and only about 55% of males living with hiv know their status (moh, 2016). the challenges with hiv testing require a new focus and new approaches to reach people with undiagnosed hiv infection. hiv self-testing (hivst) is one such innovative approach to making testing more accessible to several under-served populations such as men and key populations (who, 2013). in this regard, this study seeks to determine whether providing hivst in workplace settings will increase the uptake of hiv testing services among men employed in private security services in uganda and improve linkage to treatment and prevention services. design: cluster randomized trial in two ugandan districts participants: male employees of private security companies

Eligibility criteria:
eligibility criteria: * 18-60 years old * employed \>6 months in the private security company * men who have not tested for hiv before * men who tested hiv \>one year ago

Keywords: hiv self-testing men workplace security services linkage
efficacy of simvastatin for the treatment of copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to evaluate in patients with stable chronic obstructive pulmonary disease (copd) the efficacy of statins (simvastatin) on: (1) endothelial function; (2) systemic inflammation; (3)bode (b: body mass , o: bronchial obstruction, d: dyspnea and, e: exercise tolerance) index; (4) uric acid; and, (5)vascular growth factors. design: a 12 weeks randomized (1:1), double-blind, placebo control study. population: 18 males with stable copd between 40-80 years of age, exsmokers, with forced expiratory volume in one second (fev1) between 30 and 80% predicted post-bronchodilation.


Eligibility criteria:
inclusion criteria: * stable copd between 40-80 years of age, exsmokers, with fev1 lower that 80% predicted post-bronchodilation. exclusion criteria: * severe co-morbidity (advanced-stage cancer, tuberculosis affecting more than a third of the total lung parenchyma, pneumonectomy, pneumoconiosis, left cardiac failure previously reported, known cardiopathy with ventricular dysfunction (ejection fraction \< 45%) or any cardiovascular disease, diabetes mellitus treated with insulin, hypercholesterolemia, chronic inflammatory diseases (asthma, rheumatoid arthritis, lung fibrosis, autoimmune diseases), treatment with systemic steroid, non steroidal anti-inflammatory drugs or stains within 3 months prior to inclusion.

Keywords: chronic bronchitis statins endothelial dysfunction systemic inflammation bode index uric acid vascular growth factors
development and feasibility testing of digital theory-based pursed lip breathing in stable patients with copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the goal of this pre-post design clinical trial is to develop a digital, theory-based pursed lip breathing intervention protocol software system installed on smartphones (dt-plb) and to preliminarily evaluate its feasibility and effects in stable chronic obstructive pulmonary disease (copd). the main objectives are: 1. to develop a digital, theory-based pursed lip breathing intervention protocol software system installed on smartphones for managing breathing exercises in stable copd patients. 2. to pilot the methodological procedures of the pre-post study. 3. to determine the recruitment rate, retention rate, attrition rate, and software usage compliance during the subject recruitment and follow-up process of the pre-post study. 4. to evaluate the perception and satisfaction of copd patients using the dt-plb. 5. to preliminarily examine the effects of using the dt-plb intervention on copd patients, including the six-minute walking test, fev1% predicted, fev1/fvc, mmrc scale, copd assessment test scale, and health points. 6. to identify any potential adverse events associated with the implementation of dt-plb. participants will perform the following tasks during the intervention: 1. register a personal account on the dt-plb software. 2. acquire knowledge and skills related to pursed lip breathing by watching instructional videos. 3. practice pursed lip breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software. 4. earn health points by completing specific actions as instructed. 5. optionally post individual texts on the peer forum for peer support within the dt-plb software. 6. complete two outcome assessments as scheduled.


Eligibility criteria:
inclusion criteria: * diagnosed with copd satisfying gold criteria (agusti, 2022) ; * being chinese; * able to understand, speak, and hear; * clinically stable for at least three months prior to enrollment (soler-cataluna et al., 2018) ; * the classification of gold grades for patients is mild, moderate, and severe, which means: fev1/fvc\ 30%pre (agusti, 2022) ; * participants who were mindful about the it technology and known how to use a smartphone. exclusion criteria: * impaired hand function causing inability to use the application; * have disorders in pleural effusion, pulmonary malignancy, heart diseases, stroke with sequels; * patients who have oral or nasal diseases cannot complete the exercise.

Keywords: pursed lip breathing behavioral interventions gamification
the predictive value of prostate spherical volume ratio in lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia:a single-center paired validating confirmatory study

Conditions: Lower Urinary Tract Symptoms，Prostatic Hyperplasia

Summary: this study was a retrospective cohort study clinical trial designed to assess the predictive ability of the prostate morphometric parameter, prostate spherical volume ratio, in the lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia; and to compare the predictive ability of other anatomical parameters of the prostate (prostatic urethral length, intravesical prostatic protrusion, presumed circle area ratio, and prostate volume) in the lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia

this was a retrospective observational study approved by the ethics committee of shanghai oriental hospital. we collected patients with bph who underwent mri, urine flow measurement and completed the ipss questionnaire in our hospital between september 2022 and april 2023, measured each anatomical parameter of the patient's prostate by mri, analysed the relationship of these prostate parameters with ipss and urine flow, and conducted a follow-up of the clinical progression of the prostate in these patients to evaluate the predictive efficacy of prostate parameters for luts and clinical progression of benign prostatic hyperplasia.

Eligibility criteria:
inclusion criteria: * all patients had obvious lower urinary tract symptoms such as urinary frequency, increased nocturia, and a feeling of incomplete urination, etc. they all completed prostate mri, ipss questionnaire, and uroflowmetry for a clear diagnosis of bph. exclusion criteria: * 1, previous history of bladder, prostate, urethra surgery; 2, the existence of other diseases that cause urinary dysfunction: such as neurogenic bladder, bladder stones, urethral stenosis, urinary tract infections, acute prostatitis, etc.; 3, the existence of mental, mental disorders, can not be accurately expressed and family members can not help to improve the ipss scores; 4, to receive prostatic hyperplasia medication, such as: α-blocker therapy, 5α reductase inhibitors, etc. have not been discontinued for 6 months; 5, refused to participate in this study

Keywords: lower urinary tract symptoms，prostatic hyperplasia